AtaiBeckley Inc. Announces Merger with Eli Lilly; US HSR Waiting Period Expired

What Happened
AtaiBeckley Inc. (ATAI) filed a Form 8-K on August 31, 2026 updating progress under the Agreement and Plan of Merger dated July 15, 2026 with Eli Lilly and Company and its wholly owned merger subsidiary, Albali Acquisition Corporation. Under the agreement, Merger Sub will merge into AtaiBeckley and AtaiBeckley will become a wholly owned subsidiary of Eli Lilly if the transaction closes. The filing reports that the Hart-Scott-Rodino (HSR) waiting period in the U.S. expired at 11:59 p.m. Eastern Time on August 28, 2026.

Key Details

• Merger Agreement date: July 15, 2026 (Eli Lilly listed as Parent; Albali Acquisition Corporation as Merger Sub).
• U.S. antitrust: HSR waiting period expired Aug 28, 2026 at 11:59 p.m. ET.
• U.K.: Competition and Markets Authority (CMA) responded on Aug 21, 2026 indicating no further questions at that time.
• Australia: Australian Competition and Consumer Commission (ACCC) published a determination on Aug 27, 2026 that the merger may be consummated, subject to a 14-calendar-day waiting period expiring at 10:00 a.m. ET on Sep 10, 2026.
• The filing includes the standard cautionary forward‑looking statements and lists risks and closing conditions (e.g., required regulatory clearances, stockholder approval, satisfaction or waiver of closing conditions, and potential contingent value rights).

Why It Matters
This 8-K shows regulatory review is advancing: the U.S. HSR period has lapsed and the CMA raised no further questions, while the ACCC’s published determination sets a near-term waiting‑period milestone (Sep 10, 2026) for Australian clearance. These developments reduce some regulatory uncertainty around timing but the merger still depends on remaining approvals and other closing conditions noted in the filing. For shareholders, successful completion would make AtaiBeckley a wholly owned Eli Lilly subsidiary and could affect stock value, milestone/contingent payments and the company’s ongoing program development as described in the filing.